Skip to main content
. Author manuscript; available in PMC: 2014 Feb 4.
Published in final edited form as: Mol Pharm. 2013 Jan 14;10(2):709–716. doi: 10.1021/mp300507r

Figure 3.

Figure 3

Serial PET imaging of CD105 in 4T1 tumor-bearing BALB/c mice. (A) Serial coronal PET images at 0.5, 3, 16, 24, and 48 h post-injection of 64Cu-NOTA-TRC105-F(ab')2, or 64Cu-NOTA-TRC105-F(ab')2 after a pre-injected 1 mg dose of TRC105 (i.e. blocking). (B) A representative PET/CT image of 4T1 tumor-bearing mice at 3 h post-injection of 64Cu-NOTA-TRC105-F(ab')2. C. Serial coronal PET images at 0.5, 3, and 8 h post-injection of 61Cu-NOTA-TRC105-F(ab')2 in 4T1 tumor-bearing mice.